JHIU
ALXN

Janus Henderson Investors US’s Alexion Pharmaceuticals ALXN Stock Holding History

Janus Henderson Investors US’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$119M Buy
982,224
+62,811
+7% +$8.1M 0.1% 258
2016
Q4 		$113M Buy
919,413
+65,266
+8% +$7.99M 0.09% 268
2016
Q3 		$105M Sell
854,147
-172,238
-17% -$22.2M 0.09% 291
2016
Q2 		$120M Buy
1,026,385
+84,590
+9% +$12M 0.1% 262
2016
Q1 		$131M Buy
941,795
+189,634
+25% +$27.8M 0.11% 237
2015
Q4 		$143M Sell
752,161
-36,052
-5% -$6.3M 0.12% 217
2015
Q3 		$123M Sell
788,213
-43,682
-5% -$7.97M 0.11% 229
2015
Q2 		$150M Buy
831,895
+158,847
+24% +$27.4M 0.12% 229
2015
Q1 		$117M Buy
673,048
+306,582
+84% +$55.5M 0.1% 273
2014
Q4 		$67.8M Sell
366,466
-116,524
-24% -$21.6M 0.06% 386
2014
Q3 		$80.1M Buy
482,990
+74,887
+18% +$12.3M 0.07% 322
2014
Q2 		$63.8M Sell
408,103
-11,440
-3% -$1.81M 0.06% 360
2014
Q1 		$63.8M Sell
419,543
-977,478
-70% -$155M 0.06% 360
2013
Q4 		$186M Sell
1,397,021
-16,637
-1% -$2M 0.18% 158
2013
Q3 		$164M Sell
1,413,658
-457,736
-24% -$50.2M 0.16% 164
2013
Q2 		$173M Buy
+1,871,394
New +$180M 0.18% 149

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Janus Henderson Investors US's ALXN Position: Q1 2017 in Review

Janus Henderson Investors US increased its Alexion Pharmaceuticals (ALXN) stake by 6.8% in Q1 2017, buying an estimated $8.1M and bringing the position to 982,224 shares worth $119M. The position accounts for 0.1% of the portfolio, ranked #258.

Janus Henderson Investors US first reported a position in ALXN in Q2 2013 and has held it in 16 quarters since. The position peaked at $186M in Q4 2013. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • Janus Henderson Investors US held 982,224 shares of Alexion Pharmaceuticals worth $119M as of Q1 2017.
  • Janus Henderson Investors US bought 62,811 Alexion Pharmaceuticals shares in Q1 2017, an estimated $8.1M.
  • Alexion Pharmaceuticals made up 0.1% of Janus Henderson Investors US's portfolio in Q1 2017, its #258 holding.
  • Janus Henderson Investors US first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 16 quarters since.
  • Janus Henderson Investors US's Alexion Pharmaceuticals position peaked at $186M in Q4 2013.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.